| 1 |
Autologous 4th generation GPC3 CAR.T clinical study for advanced hepatocellular carcinoma |
| Gene Therapy |
Liver cancer |
GPC3 |
Phase 1 |
Eutilex Co.,Ltd. |
RS-2023-00283610 |
|
| 2 |
Phase 1 clinical Study of ENPP1 inhibitory Immunotherapy TXN10128 |
| Small Molecules |
Solid tumor |
ENPP1 |
Phase 1 |
Txinno Bioscience Inc. |
RS-2023-00282830 |
|
| 3 |
TC011: Clinical Phase I Trial Evaluating Safety, Pharmacokinetics, DLT, MTD, Efficacy and RP2D of TC011, a CD19.Targeted CAR.T Therapyin Relapsed or Refractory B.Cell Non.Hodgkin Lymphoma Patients |
| Gene Therapy |
B cell lymphoma |
CD19 |
Phase 1 |
TICAROS |
RS-2023-00258721 |
|
| 4 |
Phase I Clinical Study of WM-S1-030 in patients with advanced or metastatic solid tumor |
| Small Molecules |
Colorectal cancer |
mutant RON |
Phase 1 |
Wellmarkerbio Co., Ltd. |
RS-2023-00219060 |
|
| 5 |
A Phase 1b/2a Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of TU2218, an oral TGFβR Serine/Threonine Kinase Inhibitor, Administered in Combination with Pembrolizumab in Patients with Advanced Solid Tumors |
| Small Molecules |
Solid Tumor |
TGFβR1 |
Phase 1 |
Tium BIO |
RS-2022-00167091 |
|
| 6 |
Clinical Phase 1 Development of SKL27969, a Novel Brain Penetrating PRMT5 Inhibitor |
| Small Molecules |
Glioblastoma |
PRMT5 |
Phase 1 |
SK Biopharmaceuticals |
RS-2022-00165541 |
|
| 7 |
YYB-103 |
| Gene Therapy |
Glioblastoma |
IL13Rα2 |
Phase 1 |
CellabMED |
HN22C0592 |
|
| 8 |
A Phase 1/2, open-label, dose-escalation, and expansion study to evaluate safety, tolerability, pharmacokinetics, and therapeutic activity of GI-101 as a single agent and in combination with pembrolizumab, lenvatinib or local radiotherapy in patients with advanced or metastatic solid tumors (Keynote B59) |
| Recombinant Protein |
Advanced or Metastatic Solid Tumor |
CD80, IL-2 |
Phase 1 |
GI Innovation, Inc. |
HN22C0451 |
|
| 9 |
Phase I clinical study of innovative CD19-targeted CAR-T |
| Gene Therapy |
Non-Hodgkin Lymphoma |
CD19 |
Phase 1 |
AbClon Inc. |
HN22C0009 |
|
| 10 |
Completion of YBL-006 phase I trial;
a novel immune checkpoint inhibitor |
| Antibody |
Squamous cell carcinoma, Renal cell carcinoma |
PD-1 |
Phase 1 |
Y-Biologics |
HN21C1391 |
|
| 11 |
Clinical development of PSMA target therapeutic radiopharmaceutical for prostate cancer |
| Drug-conjugate |
Prostate cancer |
PSMA |
Phase 1 |
FutureChem. Co., Ltd. |
HN21C1297 |
|
| 12 |
Phase 1 clinical development of anti-cancer bispecific antibody ABL501 targeting LAG-3 and PD-L1 |
| Antibody |
NSCLC, Lung cancer, Colorectal cancer, Gastric cancer, Triple-Negative Breast Cancer, Ovarian cancer |
PD-L1, LAG-3 |
Phase 1 |
ABL Bio |
HN21C0979 |
|
| 13 |
PhaseⅠclinical development of the 4th generation NSCLC-TKI BBT-176, which targets C797S-harboring EGFR mutations |
| Small Molecules |
NSCLC |
EGFR(C797S) |
Phase 1 |
Bridge Biotherapeutics, Inc. |
HN21C0859 |
|
| 14 |
Clinical trial and drug approval of the next generation CD19 CAR-T designed to overcome immune-suppressive environment |
| Gene Therapy |
Non-small cell lymphoma |
CD19 |
Phase 1 |
Curocell Inc. |
HN21C0653 |
|
| 15 |
Phase 1 clinical trial of CKD-702, bispecific antibody, in NSCLC |
| Antibody |
NSCLC |
c-MET, EGFR |
Phase 1 |
Chong Kun Dang pharmaceutical Corp. |
HN21C0551 |
|
